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Summary 
Background: Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously 
shown efficacy in a phase 2 study (capsule formulation) in patients with platinum-
sensitive, relapsed high-grade serous ovarian cancer. 
Methods: This randomised, double-blind, phase 3 study (SOLO2; ENGOT Ov-21; 
NCT01874353) evaluated olaparib tablet maintenance treatment in platinum-sensitive, 
relapsed ovarian cancer patients with mutation in BRCA1 and/or BRCA2 (BRCA1/2m). 
Primary endpoint was investigator-assessed progression-free survival (PFS). Patients 
were randomised 2:1 to olaparib (300 mg twice daily) or placebo.  
Findings: 294/295 randomised patients received study treatment (olaparib, n=195; 
placebo, n=99). PFS was significantly longer with olaparib than placebo when evaluated 
by investigator assessment (hazard ratio [HR] 0·30, 95% confidence interval [CI] 0·22–
0·41; p<0·0001; median 19·1 vs 5·5 months) and blinded independent central review 
(HR 0·25, 95% CI 0·18–0·35; p<0·0001; median 30·2 vs 5·5 months). Supportive 
secondary endpoints demonstrated significant benefit for olaparib: time to first 
subsequent therapy or death, HR 0·28 (p<0.0001); time to second progression (PFS2), 
HR 0·5 (p=0·0002); time to second subsequent therapy or death, HR 0.37 (p<0·0001). 
Most common grade ≥3 adverse events: anaemia (olaparib, 38 patients [19·5%]; 
placebo, 2 patients [2·0%]), fatigue/asthenia (olaparib, 8 patients [4·1%]; placebo, 2 
patients [2·0%]), and neutropenia (10 patients, 5.1%; placebo, 4 patients [4·0%]). 
Toxicities led to olaparib dose reductions in 49 patients (25.1%) and discontinuation in 
21 patients (10.8%). Patients’ quality of life, measured by the Trial Outcome Index of the 
Functional Assessment of Cancer Therapy – Ovarian Cancer, showed no appreciable 
difference between treatment groups. 
Interpretation: Olaparib tablet maintenance treatment provided a statistically significant 
PFS improvement with no detrimental effect on quality of life in patients with platinum-
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sensitive, relapsed ovarian cancer and a BRCA1/2m. Secondary endpoints of TFST, 
PFS2, and TSST demonstrated statistically significant benefit in favour of olaparib. 
Excepting anaemia, toxicities with olaparib were low grade and manageable.  
Funding: AstraZeneca 
Word count: 299/300 
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Introduction 
Patients with advanced ovarian cancer often respond well to first-line chemotherapy, 
with the duration of benefit usually ranging from 4 to 6 months.
1–3
 Following disease 
recurrence however, this period becomes progressively shorter with the successive 
treatments given at each subsequent relapse. There is a significant unmet need for well-
tolerated therapies that can improve long-term disease control in patients with recurrent 
ovarian cancer.  
Olaparib is the first-in-class oral poly(ADP-ribose) polymerase (PARP) inhibitor. The 
inhibition of PARP is a potential synthetic lethal therapeutic strategy for the treatment of 
cancers characterised by specific DNA-repair defects, such as tumour cells that harbour 
a BRCA1 and/or a BRCA2 (BRCA1/2) mutation and are rendered deficient in 
homologous recombination repair.
4,5
 In homologous recombination-deficient tumours, 
PARP inhibition eliminates an alternative DNA repair pathway essential for maintaining 
viability, leading to tumour cell death. The estimated prevalence of a BRCA1/2 mutation 
in patients with newly diagnosed high-grade serous ovarian cancer (HGSOC) is 20–
25%; it may be higher in patients with platinum-sensitive, relapsed ovarian cancer.
6–9
 
Olaparib (capsule formulation) is currently approved in the EU and other countries as 
maintenance treatment for patients with platinum-sensitive, relapsed ovarian cancer and 
a germline and/or somatic BRCA1/2 mutation, and in the USA as monotherapy for 
advanced ovarian cancer patients with a germline BRCA1/2 mutation.
10,11
   
Previous studies have indicated the effectiveness of olaparib in the setting of platinum-
sensitive, relapsed, HGSOC. Study 19 (NCT00753545) was a randomised controlled 
phase 2 trial of olaparib capsules given as maintenance monotherapy to 265 patients 
where it provided a significant improvement in progression-free survival (PFS), 
compared with placebo, in the total study population (hazard ratio [HR] 0·35; 95% 
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confidence interval [CI] 0·25–0·49; p<0·001). A pre-planned retrospective analysis of 
Study 19 patients by BRCA status suggested that those with a BRCA1/2 mutation 
derived the greatest PFS benefit from olaparib treatment (HR 0·18; 95% CI 0·10–0·31; 
p<0·0001).
2,12
 Study 19 also demonstrated the long-term benefit and tolerability profile of 
olaparib in the maintenance setting.
13
  
The SOLO2/ENGOT Ov-21 trial that we describe here was designed to prospectively 
confirm the findings seen in Study 19 in a similar disease setting: it is a randomised, 
international, multicentre, phase 3 trial to evaluate olaparib maintenance treatment in 
patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation. 
SOLO2 uses a tablet formulation of olaparib that offers patients a reduced daily pill 
burden compared with capsule. An adaptive-design phase 1 trial of olaparib 
bioavailability (Study 24) has previously established that olaparib exposure with a 300 
mg twice daily [bid] tablet dose was comparable to, or higher than, exposure in patients 
receiving olaparib 400 mg bid capsule.
14
 The findings from Study 24 informed the tablet 
dose regimen adopted in SOLO2 and other phase 3 olaparib studies.
14
  
Efficacy and safety data from the primary analysis of SOLO2/ENGOT Ov-21 are 
reported.  
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Methods 
Study design and participants 
This was a randomised, double-blind, placebo-controlled, international, multicentre, 
phase 3 study (SOLO2/ENGOT-Ov21, NCT01874353, D0816C00002), conducted by 
the European Network for Gynaecological Oncological Trial groups (ENGOT) across 123 
sites in 16 countries. Eligible patients were aged ≥18 years with histologically confirmed, 
relapsed, HGSOC or high-grade endometrioid cancer, including primary peritoneal 
and/or fallopian tube cancer. Patients had received at least two previous lines of 
platinum-based chemotherapy and were in radiological response (either complete 
response [CR] or partial response [PR]) to their most recent regimen. In addition, 
patients were required to have platinum-sensitive disease (disease progression 
occurring at least 6 months after the last dose of platinum therapy was given) following 
their penultimate line of chemotherapy before enrolment. 
Patients were required to have a predicted deleterious, or suspected deleterious, 
BRCA1/2 mutation based on either blood or tumour testing and all patients consented to 
provide two blood samples for confirmatory germline BRCA1/2 mutation testing using 
Myriad BRACAnalysis
®
 (Myriad Genetics, Salt Lake City, UT, USA).  Patients with a 
known BRCA1/2 mutation before randomisation could enter the trial based on this 
information; patients with unknown BRCA1/2 mutation status were screened prior to 
randomisation. All patients randomised in SOLO2 harboured a germline BRCA1/2 
mutation. All patients provided written, informed consent. This study was performed in 
accordance with the Declaration of Helsinki and Good Clinical Practice.
15
 Additional 
eligibility criteria are provided in the Methods of the Supplementary Appendix. 
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Randomisation and masking 
Eligible patients were randomised (2:1) to receive olaparib tablet maintenance 
monotherapy, or matching placebo. An adaptive-design phase 1 trial of olaparib 
bioavailability (Study 24) has previously established that olaparib exposure with a 300 
mg twice daily [bid] tablet dose was comparable to, or higher than, exposure in patients 
receiving olaparib 400 mg bid capsule.
14
 The randomisation scheme was produced by a 
computer software program that generates random numbers (Global Randomisation 
System) and was loaded into an interactive voice and web response system 
(IVRS/IWRS) database. Randomisation using IVRS/IWRS was completed within 8 
weeks of the patients’ last dose of chemotherapy, and was stratified by response to 
previous chemotherapy (CR or PR) and length of platinum-free interval (6–12 months or 
≥12 months). Treatment masking was achieved using individual treatment codes 
assigned by the IVRS/IWRS. Treatment assignment was masked for patients, those 
giving the interventions, data collectors, and data analysers. Olaparib and placebo 
tablets looked identical and were presented in the same packaging. 
 
Procedures 
Patients received either oral olaparib maintenance monotherapy (300 mg bid, tablets 
[manufactured by AstraZeneca]) or placebo (bid, tablets) until disease progression or 
until the investigator deemed that a patient was no longer benefiting from treatment. 
After a discontinuation of study treatment in SOLO2, the investigator was responsible for 
selecting a patient’s subsequent treatments. 
Patients were assessed using computed tomography (CT) or magnetic resonance 
imaging (MRI) scans every 12 weeks until week 72, and then every 24 weeks thereafter 
until objective disease progression; CT/MRI scans were also sent to a Clinical Research 
Organisation for blinded independent central review (BICR). After progression, patients 
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were followed every 12 weeks for second progression and survival. The primary 
endpoint for patient-reported health-related quality of life (HRQoL) was Trial Outcome 
Index (TOI) score, derived from the Functional Assessment of Cancer Therapy – 
Ovarian Cancer (FACT-O) questionnaire; patient-reported health state utility was 
assessed as an exploratory objective using the EuroQoL five dimensions five level 
questionnaire. Questionnaires were collected every 12 weeks for either 24 months or 
until the data cut-off for the primary analysis (whichever occurred first). Safety was 
monitored by recording adverse events (AEs), measuring vital signs, and by performing 
physical examinations. AEs were graded according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events v4.0 (CTCAE). 
 
Outcomes 
The primary endpoint for this trial was investigator assessment of PFS, defined as the 
time from randomisation until objective radiological disease progression or death using 
modified Response Evaluation Criteria in Solid Tumours v1·1. A sensitivity analysis of 
PFS was conducted by BICR. Secondary endpoints included investigator assessment of 
time to second progression (PFS2), determined by objective radiological, CA-125, or 
symptomatic progression; time to first subsequent therapy or death (TFST); time to 
second subsequent therapy or death (TSST); overall survival (OS); objective response 
rate; HRQoL; and safety and tolerability. 
 
Statistical analysis 
Analyses were to be performed on a higher number of events than required for a 
powered superiority analysis for both PFS and PFS2; therefore, the power to show 
superiority for both endpoints was >90%. In total, 192 events of progression or death 
(~65% maturity) were required to provide sufficient precision of the estimated HR. PFS 
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was tested at a two-sided significance level of 5% and analysed with a log-rank test, 
using the stratification factors used for randomisation. PFS2 and OS were analysed at 
the time of primary analysis of PFS, using the same methodology. At this initial analysis, 
statistical significance was to be declared for PFS2 if one-sided p<0·0125 and for OS if 
one-sided p<0·0001. Efficacy data were analysed in the intention-to-treat population, 
which included all randomised patients (full analysis set). Safety was analysed in all 
patients from the intention-to-treat population who received at least one dose of study 
treatment (safety analysis set). The statistical analysis plan is available at Lancet.org. 
This trial is registered with ClinicalTrials.gov, identifier NCT01874353, and is closed to 
new participants. 
 
Role of the funding source 
The trial design was a collaboration between Groupe d’Investigateurs National des 
Etudes des Cancers Ovariens et du sein (GINECO), ENGOT, and the sponsor, 
AstraZeneca. This article was written by the authors, with medical writing support funded 
by the sponsor. All authors had full access to the raw data and had roles in data 
collection, analysis, interpretation, and manuscript writing. The decision to submit the 
manuscript for publication was made by all the authors. The corresponding author (EP-
L) had final responsibility for the decision to submit for publication. 
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Results 
Between 3 September 2013 and 21 November 2014, 295 patients were randomised 
(figure 1). At the data cut-off (19 September 2016), 294 patients had received study 
treatment (olaparib group, n=195; placebo group, n=99) and 83/195 (42·6%) patients 
were receiving ongoing treatment with olaparib, compared with 13/99 (13·1%) patients 
remaining on placebo. Demographic and baseline characteristics were well balanced 
between the two groups (table 1). 153/196 patients (78·1%) in the olaparib group and 
83/99 patients (83·8%) in the placebo group had a previously known BRCA1/2 mutation, 
and could be enrolled based on this information. All patients received a confirmatory 
BRCA test as part of the trial and, overall, 190/196 (96·9%) of patients in the olaparib 
group and 96/99 (97·0%) in the placebo group had a confirmed germline BRCA1/2 
mutation. No patients had a confirmed somatic BRCA1/2 mutation. Details of treatment 
duration and dose intensity are provided in the Results section of the Supplementary 
Appendix. 
Efficacy  
This analysis was performed after 187 investigator-assessed events of disease 
progression or death (63% maturity: olaparib group, 107/196 [54·6%]; placebo group, 
80/99 [80·8%]). The actual number of PFS events was 2·6% lower than the number of 
PFS events detailed in the statistical plan (~192 events). The median follow-up for PFS 
was 22·1 months (interquartle range [IQR] 21·9–27.4) in the olaparib group and 
22·2 months (IQR 8.3–27.5) for placebo. Investigator-assessed PFS showed a 
statistically significant improvement in favour of olaparib with a HR of 0·30 (95% CI 0·22 
to 0·41, p<0·0001; median 19·1 [IQR 8.3–33.2] months olaparib group vs 5·5 [IQR 2.9–
10.4] months placebo group) (figure 2A). The proportion of patients who had not 
experienced disease progression in the olaparib group after 12 months and 24 months 
was 65·1% and 43·0%, respectively, compared with 20·9% and 15·1%, respectively, in 
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the placebo group. The sensitivity analysis of PFS by BICR (151/295 events [51% 
maturity]) also demonstrated a significant improvement for PFS in patients receiving 
olaparib versus patients on placebo, with a HR of 0·25 (95% CI 0·18 to 0·35, p<0·0001; 
median 30·2 [IQR 8·4–non calculable] months vs 5·5 [IQR 2.8–10.2 months]) (figure 
2B).  
Several secondary endpoints also demonstrated a statistically significant improvement 
for olaparib. Analysis of TFST (171/295 events [58% maturity]) gave a HR of 0·28 (95% 
CI 0·21 to 0·38, p<0·0001; median 27·9 [IQR 11·3–34·5] months vs 7·1 [IQR 4·9–16·0] 
months) for olaparib relative to placebo (figure 3A). PFS2 (119/295 events [40% 
maturity]) demonstrated a HR of 0·50 (95% CI 0·34 to 0·72, p=0·0002; median not 
reached vs 18·4 [IQR 12·7–27·5] months) in favour of olaparib, and a HR benefit of 0·37 
(95% CI, 0·26 to 0·53, p<0·0001; median not reached vs 18·2 [IQR 12·6–not calculable] 
months) was observed for TSST (128/295 events [43% maturity]) in the direction of 
olaparib (figure 3B, C). The immature OS data (72/295 events [24% maturity]) showed 
no detriment for patients receiving olaparib, and a HR that numerically favoured olaparib 
treatment (HR 0·80; 95% CI 0·50 to 1·31, p=0·4267; medians not reached).   
Patient-reported outcomes 
Patient-reported outcomes showed no appreciable difference in quality of life for patients 
receiving olaparib compared with those receiving placebo. The primary analysis 
measure, the mean change from baseline in TOI of the FACT-O, was similar in both 
groups over the first 12 months (adjusted mean, –2·90 months [95% CI –4·13 to –1·67] 
vs –2·87 months [95% CI –4·64 to –1·10]; estimated difference, –0·03 months [95% CI –
2·19 to 2·13] p=0·98). Additional quality of life data will be published separately. 
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Safety and tolerability 
AEs (all CTCAE grades) reported in >20% of patients in either treatment group are 
shown in table 2. The most common toxicities observed (all grades) were nausea 
(olaparib, 148/195 patients [75·9%]; placebo, 33/99 patients [33·3%]), fatigue/asthenia 
(olaparib, 128/195 [65·6%]; placebo, 39/99 patients [39·4%]), anaemia (olaparib, 85/195 
[43·6%]; placebo 8/99 patients [8.1%]), vomiting (olaparib, 73/195 [37·4%]; placebo, 
19/99 patients [19.2%]), and diarrhoea (olaparib, 64/195 [32·8%]; 20/99 patients 
[20.2%]), however the overall incidence of grade >3 toxicity was low (olaparib, 72/195 
patients [36·9%)]; placebo, 18/99 patients [18·2%]). The most common grade ≥3 AE was 
anaemia (olaparib, 38/195 patients [19·5%]; placebo, 2/99 [2·0%]). 35/195 (17·9%) 
patients in the olaparib group had a blood transfusion compared with 1/99 (1·0%) 
patients in the placebo group. The incidence of grade ≥3 neutropenia and 
thrombocytopenia did not increase on olaparib treatment (table 3): neutropenia, 10/195 
patients (5·1%) in the olaparib group versus 4/99 patients (4.0%) in the placebo group; 
thrombocytopenia, 2/195 (1·0%) patients in the olaparib group versus 1/99 patients 
(1·0%) in the placebo group.  
Serious AEs were experienced by 35/195 (17·9%) patients in the olaparib group and 
8/99 (8·1%) patients in the placebo group. One patient (1/195 [0·5%]) in the olaparib 
group had an AE (acute myeloid leukaemia [AML]) with an outcome of death. The rate of 
secondary malignancies for the long-term follow-up period was 7/195 patients (3·6%) in 
the olaparib group and 5/99 patients (5·1%) in the placebo group (supplementary table 
1). The incidence of AML, myelodysplastic syndrome (MDS), and chronic 
myelomonocytic leukaemia (CMML) for the long-term follow-up period was 4/195 
patients (2·1%) in the olaparib group (AML, 2/195 patients [1·0%]; MDS, 1/195 patients 
[0·5%]; CMML, 1/195 patients [0·5%]) and 4/99 patients (4·0%) in the placebo group 
(AML, 1/99 patients [1·0%]; MDS, 3/99 patients [3·0%]).   
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The frequency of AEs leading to dose interruptions was 88/195 (45·1%) patients in the 
olaparib group versus 18/99 (18·2%) patients for placebo (table 3). Dose reductions 
following AEs were required for 49/195 (25·1%) patients and 3/99 (3·0%) patients in the 
olaparib and placebo groups, respectively. The proportion of patients that discontinued 
study treatment because of toxicity was 21/195 (10·8%) in the olaparib group compared 
with 2/99 (2·0%) patients in the placebo group; anaemia (6/195 patients, 3·1%) and 
neutropenia (2/195 patients, 1·0%) were the most common AEs leading to 
discontinuation in the olaparib group. 
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Discussion 
In this randomised, double-blind, phase 3 study, olaparib maintenance treatment in 
patients with platinum-sensitive, relapsed ovarian cancer led to a statistically significant 
improvement in PFS, as evaluated both by the primary endpoint of investigator 
assessment and by BICR. In addition, analysis of patient-reported outcomes showed 
that maintenance treatment with olaparib had no detrimental effect on patients’ quality of 
life. The improvement in PFS seen using the olaparib tablet formulation in this disease 
setting is compelling because patients were able to maintain a good quality of life while 
experiencing a delay in disease progression and, therefore, the symptoms associated 
with subsequent chemotherapy treatments. 
The effect on PFS observed in our trial is comparable to that reported with other PARP 
inhibitors in phase 2 and phase 3 trials in similar clinical settings; however, such indirect 
comparisons cannot be considered definitive, particularly because of differences 
between the patient populations.
16–18
 The sensitivity analysis of PFS by BICR, which was 
conducted to account for any potential bias from the investigator assessment, was 
consistent with the investigator-assessed primary endpoint. The HR observed in the 
sensitivity analysis was numerically slightly superior (0·25 vs 0·30). The larger median 
PFS derived from the BICR analysis compared with the investigator assessment was 
possibly driven by informative censoring, whereby some patients who had progressed 
according to investigator assessment had not yet been shown to progress by BICR 
because scans were performed every 12 weeks only, prior to submission for BICR 
assessment. The SOLO2 sensitivity analysis that adjusted conservatively for informative 
censoring resulted in a median PFS by BICR that was similar to the investigator 
assessment (further details are available in the Methods and Results of the 
Supplementary Appendix). Our study also showed a statistically significant improvement 
in TFST, PFS2 and TSST in favour of olaparib. The timing of TFST typically marks a 
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significant treatment shift for patients with recurrent ovarian cancer, from an oral PARP 
inhibitor to intravenous chemotherapy, whilst the analysis of TSST suggests that patients 
reach their second subsequent treatment without the potential occurrence of 
chemotherapy resistance countering the benefit they originally received on olaparib 
maintenance treatment. Of the secondary endpoints presented here, TFST and TSST 
may therefore be especially clinically meaningful.
19,20
 The OS data were immature (24% 
maturity) at the time of this analysis and an additional analysis is planned at 
approximately 60% maturity (~177 OS events).  
Maintenance monotherapy with olaparib was previously evaluated in Study 19, which 
demonstrated a significant treatment benefit in both the overall study population 
(patients with platinum-sensitive, relapsed ovarian cancer) and the subpopulation of 
patients harbouring a BRCA1/2 mutation.
2
 Our SOLO2 data support the treatment 
benefit observed in Study 19 for patients with a BRCA1/2 mutation, using a two-tablet 
bid dosing schedule of olaparib. 
Overall, the safety profile of the olaparib tablet was similar to that observed with the 
approved capsule formulation of olaparib.
12
 The rate of grade ≥3 anaemia was higher in 
SOLO2, however these data could be explained by the longer exposure to olaparib for 
patients in SOLO2, versus Study 19. The incidence of olaparib discontinuation (21 
patients, [10.8%]) due to AEs showed that toxicity related to the 300 mg bid 
maintenance olaparib tablet dose was manageable in most of these patients with dose 
modifications. Use of the 300 mg bid tablet dose in SOLO2 reduces the pill burden from 
16 capsules to 4 tablets per day, providing a more convenient regimen for patients.
14
 
Several of the most common adverse events observed in patients receiving olaparib in 
SOLO2, namely fatigue, nausea, anemia, and vomiting, are considered to be class 
effects with a PARP inhibitor.
16–18 
The rates of grade ≥3 neutropenia were comparable 
between the olaparib and placebo groups in SOLO2. Notably, some common grade ≥3 
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AEs, such as thrombocytopenia, tachycardia, and liver enzyme elevation (alanine 
aminotransferase or aspartate aminotransferase increased), which has been reported by 
>10% of PARP inhibitor-treated patients in other trials, was reported in ≤1% of olaparib-
treated patients in our trial.
16–18
 The rates of tachycardia, hypertension, anxiety, and 
insomnia were not increased in the olaparib group verus placebo. Taken together, these 
data highlight that olaparib does not show a significant interaction with liver or 
cardiovascular function, and does not have an appreciable direct negative effect on 
psychological function. Long-term follow-up data demonstrated that the incidence of
 
secondary malignancies, including MDS/AML/CMML, was also comparable between 
both treatment groups in SOLO2.
 
 
Conclusions 
SOLO2/ENGOT Ov-21 provides the first phase 3 data for olaparib tablets as 
maintenance treatment in patients with platinum-sensitive, relapsed, serous ovarian 
cancer. Our results confirm that olaparib can achieve a significant prolongation of PFS 
with no detrimental effect on quality of life in this patient population. The favorable safety 
profile in SOLO2 enabled the majority of patients receiving olaparib to maintain full 
dosing throughout their maintenance treatment. 
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Research in context 
Evidence before this study 
We conducted searches of PubMed and the databases of the American Society of 
Clinical Oncology, European Cancer Organisation, European Society of Gynaecological 
Oncology, European Society for Medical Oncology, and Society of Gynaecological 
Oncology to find journal publications and conference abstracts published between 1 
January 2016 and 1 January 2017, including the search terms “poly(ADP-ribose) 
polymerase inhibitor” or “PARP inhibitor” and “ovarian cancer”, using no language 
restrictions. PARP inhibitors in late clinical development are olaparib, niraparib, 
rucaparib, talazoparib, and veliparib. In a phase 2 study (NCT00753545, D0810C00019 
[Study 19]), patients with platinum-sensitive, relapsed ovarian cancer treated with the 
oral PARP inhibitor olaparib as maintenance monotherapy (capsule formulation) had 
significantly increased PFS compared with those treated with placebo, with the greatest 
PFS benefit seen in patients with a BRCA1/2 mutation. 
 
Added value of this study 
Study 19 provided evidence in phase 2 that patients with platinum-sensitive, relapsed 
ovarian cancer can benefit from olaparib maintenance treatment with the capsule 
formulation of olaparib. Patients with a BRCA1/2 mutation derived the greatest PFS 
improvement in Study 19, as demonstrated by a pre-specified, retrospective analysis. 
This phase 3 study (NCT01874353, SOLO2, ENGOT Ov-21), the largest study of 
olaparib maintenance treatment in patients with platinum-sensitive, relapsed ovarian 
cancer, has recruited patients with a BRCA1/2 mutation. Efficacy data for SOLO2 shows 
a statistically significant improvement in median PFS with maintenance olaparib 
compared with placebo, by investigator assessment and BICR, which substantially 
exceeded the PFS benefit seen with olaparib in Study 19. We also observed significant 
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improvement in PFS2, and a statistically significant and clinically meaningful 
improvement in TFST and TSST. Patients received a new tablet formulation of olaparib 
in SOLO2. Olaparib tablets reduce the pill burden from 16 capsules to four tablets per 
day whilst maintaining comparable or higher exposure, providing patients with a simpler, 
more convenient treatment regime. Maintenance treatment with the olaparib tablet 
formulation was well tolerated, with no new safety signals and manageable toxicities. In 
addition, no significant difference in patients’ quality of life was reported with olaparib 
compared with placebo. 
 
Implications of all of the available evidence 
We report here the first phase 3 data for the newer tablet formulation of olaparib as 
monotherapy, rather than the capsule formulation, and the first phase 3 data for olaparib 
in patients with ovarian cancer. The sensitivity analysis of PFS by BICR showed the 
greatest median improvement in PFS observed to date for a PARP inhibitor in this 
clinical setting, and resulted in a lower HR (HR=0·25, 95% CI 0·18–0·35) than the 
investigator-assessed primary endpoint (HR=0·30, 95% CI 0·22–0·41). Both 
assessments of PFS demonstrated a PFS benefit with olaparib that substantially 
exceeded that seen in phase 2 investigation in patients with platinum-sensitive, relapsed 
ovarian cancer and a BRCA1/2 mutation in Study 19. The SOLO2 data support use of 
the olaparib tablet formulation, which was shown to have a similar safety profile to that 
previously seen with the approved capsule formulation of olaparib. The tablet dose used 
in SOLO2 significantly reduces the pill burden from 16 capsules to four tablets per day, 
providing a convenient olaparib regimen that may contribute to improved patient 
compliance. Given the limited treatment options available for patients with platinum-
sensitive, relapsed ovarian cancer, the data for olaparib as maintenance therapy in 
SOLO2 are notable: patients demonstrated a delay in disease progression while 
 20 
experiencing no change in their quality of life. Additional clinical studies using the 
olaparib tablet formulation are ongoing. 
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Table 1: Baseline and demographic characteristics 
Characteristic  Olaparib 300 mg 
bid 
(n=196) 
Placebo 
(n=99) 
Age, years   56 (51–63) 56 (49–63) 
ECOG performance status 0 162 (82·7%) 77 (77·8%) 
 1 32 (16·3%) 22 (22·2%) 
 Missing  2 (1·4%) 0 
Primary tumour location  Ovary  164 (83·7%) 86 (86·9%) 
 
Fallopian tubes or 
primary peritoneal 
31 (15·8%) 13 (13·1%) 
 Missing 1 (0·5%) 0 
Histology type Serous 183 (93·4%) 86 (86·9%) 
 Endometrioid  9 (4·6%) 8 (8·1%) 
 Mixed  3 (1·5%) 5 (5·1%) 
 Missing 1 (0·5%) 0 
Patients with >2 cm target 
lesions at baseline 
Yes 30 (15·3%) 18 (18·2%) 
Confirmed germline BRCA 
mutation 
 
BRCA1 132 (67·3%) 61 (61·6%) 
 BRCA2 58 (29·6%) 35 (35·4%) 
 Both 0 0 
 Missing* 6 (3·1%) 3 (3·0%) 
Response to previous platinum 
therapy 
CR  91 (46·4%) 47 (47·5%) 
 PR  105 (53·6%) 52 (52·5%) 
Number of prior platinum 
regimens 
2  110 (56·1%) 62 (62·6%) 
 3  60 (30·6%) 20 (20·2%) 
 26 
Characteristic  Olaparib 300 mg 
bid 
(n=196) 
Placebo 
(n=99) 
 4  18 (9·2%) 12 (12·1%) 
 ≥5  7 (3·5%) 5 (5·0%) 
Platinum-free interval >6–12 months  79 (40·3%) 40 (40·4%) 
 >12 months 117 (59·7%) 59 (59·6%) 
Data are number (%) or median (IQR). CR=complete response. ECOG=Eastern Cooperative 
Oncology Group. PR=partial response. *Denotes patients with a confirmed germline BRCA1/2 
mutation by local testing, but without confirmed germline BRCA1/2 mutation status as part of this trial. 
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Table 2: Non-haematological adverse events (any grade) in ≥20% of patients in either treatment group and haematological AEs 
(any grade) occurring in ≥10% of patients are shown, together with the respective incidence of grade ≥3 adverse events   
Event* Olaparib (n=195) Placebo (n=99) 
All grades Grade ≥3 All grades Grade ≥3 
Patients with any adverse event 192 (98·5%) 72 (36·9%) 94 (94·9%) 18 (18·2%) 
Non-haematological adverse events     
Nausea 148 (75·9%) 5 (2·6%) 33 (33·3%) 0 
Fatigue/asthenia* 128 (65·6%) 8 (4·1%) 39 (39·4%) 2 (2·0%) 
Vomiting 73 (37·4%) 5 (2·6%) 19 (19·2%) 1 (1·0%) 
Diarrhoea  64 (32·8%) 2 (1·0%) 20 (20·2%) 0 
Dysgeusia 52 (26·7%) 0 7 (7·1%) 0 
Headache 49 (25·1%) 1 (0·5%) 13 (13·1%) 0 
Abdominal pain 47 (24·1%) 5 (2·6%) 31 (31·3%) 3 (3·0%) 
Decreased appetite 43 (22·1%) 0 11 (11·1%) 0 
Constipation 40 (20·5%) 0 23 (23·2%) 3 (3·0%) 
Haematological adverse events     
Anaemia
†
 85 (43·6%) 38 (19·5%) 8 (7·1%) 2 (2·0%) 
Neutropenia
‡
 38 (19·5%) 10 (5·1%) 6 (6·1%) 4 (4·0%) 
 28 
Thrombocytopenia
§
 27 (13·8%) 2 (1·0%) 3 (3·0%) 1 (1·0%) 
Data are number (%). Where indicated, the Medical Dictionary for Regulatory Activities (MedDRA) preferred terms for some adverse events have been 
combined. *Includes patients with fatigue and patients with asthenia; 
†
includes patients with anaemia, haemoglobin decreased, haematocrit decreased, and 
red blood cell count decreased. 
‡
Includes patients with neutropenia, febrile neutropenia, neutropenic sepsis, neutrophil count decreased, granulocytopenia, 
and granulocyte count decreased. 
§
Includes patients with thrombocytopenia, platelet count decreased, and plateletcrit decreased. 
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Table 3:  Dose modifications owing to adverse events and dose discontinuations owing to adverse events 
 
Patient compliance, n (%) Olaparib (n=195) Placebo (n=99) 
Dose interruptions  88 (45·1%) 18 (18·2%) 
Dose reductions  49 (25·1%) 3 (3·0%) 
Discontinuations  21 (10·8%) 2 (2·0%) 
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Figure legends 
Figure 1: Patient enrolment and outcomes 
Figure 2: Kaplan–Meier estimates of (A) PFS by investigator assessment 
(B) PFS by BICR  
BICR=blinded independent central review. PFS=progression-free survival. 
Figure 3: Kaplan–Meier estimates of (A) TFST (B) PFS2 and (C) TSST 
CI=confidence interval. PFS2=time to second progression. NR=not reported. TFST=time to 
first subsequent therapy or death. TSST=time to second subsequent therapy or death. 
602 patients enrolled
295 randomly assigned
99 assigned to placebo
99 received study treatment
13 on study treatment at 
data cut-off
83 on study treatment at
data cut-off
196 assigned to olaparib
195 received treatment
1 did not receive treatment
307 not randomised
293 did not meet
eligibility criteria
4 patient decision
4 lost to follow-up
6 other
86 discontinued treatment
2 adverse events
76 objective disease
progression
4 patient decision
4 other
112 discontinued treatment
22 adverse events
75 objective disease
progression
5 patient decision
10 other
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